» Articles » PMID: 28133653

Personalized Protein Corona on Nanoparticles and Its Clinical Implications

Overview
Journal Biomater Sci
Date 2017 Jan 31
PMID 28133653
Citations 84
Authors
Affiliations
Soon will be listed here.
Abstract

It is now well understood that once in contact with biological fluids, nanoscale objects lose their original identity and acquire a new biological character, referred to as a protein corona. The protein corona changes many of the physicochemical properties of nanoparticles, including size, surface charge, and aggregation state. These changes, in turn, affect the biological fate of nanoparticles, including their pharmacokinetics, biodistribution, and therapeutic efficacy. It is progressively being accepted that even slight variations in the composition of a protein source (e.g., plasma and serum) can substantially change the composition of the corona formed on the surface of the exact same nanoparticles. Recently it has been shown that the protein corona is strongly affected by the patient's specific disease. Therefore, the same nanomaterial incubated with plasma proteins of patients with different pathologies adsorb protein coronas with different compositions, giving rise to the concept of personalized protein corona. Herein, we review this concept along with recent advances on the topic, with a particular focus on clinical relevance.

Citing Articles

Inflammatory disease progression shapes nanoparticle biomolecular corona-mediated immune activation profiles.

Shaw J, Caprio N, Truong N, Weldemariam M, Tran A, Pilli N Nat Commun. 2025; 16(1):924.

PMID: 39843415 PMC: 11754911. DOI: 10.1038/s41467-025-56210-4.


Effect of Lipid Nanoparticle Physico-Chemical Properties and Composition on Their Interaction with the Immune System.

Catenacci L, Rossi R, Sechi F, Buonocore D, Sorrenti M, Perteghella S Pharmaceutics. 2025; 16(12.

PMID: 39771501 PMC: 11728546. DOI: 10.3390/pharmaceutics16121521.


Inflammation-Modulating Biomedical Interventions for Diabetic Wound Healing: An Overview of Preclinical and Clinical Studies.

Mahmoud N, Hamad S, Shraim S ACS Omega. 2024; 9(45):44860-44875.

PMID: 39554458 PMC: 11561615. DOI: 10.1021/acsomega.4c02251.


The role of patient-specific variables in protein corona formation and therapeutic efficacy in nanomedicine.

Cisneros E, Morse B, Savk A, Malik K, Peppas N, Lanier O J Nanobiotechnology. 2024; 22(1):714.

PMID: 39548452 PMC: 11566257. DOI: 10.1186/s12951-024-02954-y.


Patient-Specific Nanoparticle Targeting in Human Leukemia Blood.

Ju Y, Li S, Tan A, Pilkington E, Brannon P, Plebanski M ACS Nano. 2024; 18(42):29021-29035.

PMID: 39380440 PMC: 11503784. DOI: 10.1021/acsnano.4c09919.


References
1.
Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, Byers H . Proteome-based plasma biomarkers for Alzheimer's disease. Brain. 2006; 129(Pt 11):3042-50. DOI: 10.1093/brain/awl279. View

2.
Hajipour M, Raheb J, Akhavan O, Arjmand S, Mashinchian O, Rahman M . Personalized disease-specific protein corona influences the therapeutic impact of graphene oxide. Nanoscale. 2015; 7(19):8978-94. DOI: 10.1039/c5nr00520e. View

3.
Han S, Newsome B, Hennig B . Titanium dioxide nanoparticles increase inflammatory responses in vascular endothelial cells. Toxicology. 2013; 306:1-8. PMC: 3631470. DOI: 10.1016/j.tox.2013.01.014. View

4.
Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B . Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res. 2007; 13(3):920-8. DOI: 10.1158/1078-0432.CCR-06-1695. View

5.
Addona T, Abbatiello S, Schilling B, Skates S, Mani D, Bunk D . Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol. 2009; 27(7):633-41. PMC: 2855883. DOI: 10.1038/nbt.1546. View